NeuroPace, Inc. (NASDAQ:NPCE) Stock Has Consensus Target Price of $19.33

NeuroPace, Inc. (NASDAQ:NPCE) has received an average rating of “Moderate Buy” from the ten brokerages that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, seven have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $19.33.

A number of equities analysts recently weighed in on NPCE shares. HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of NeuroPace in a research note on Wednesday, July 29th. KeyCorp assumed coverage on shares of NeuroPace in a research report on Thursday, September 17th. They set an “overweight” rating and a $18.00 price objective for the company. Mizuho initiated coverage on shares of NeuroPace in a research note on Thursday, July 23rd. They issued an “outperform” rating and a $22.00 target price for the company. Guggenheim reaffirmed a “neutral” rating on shares of NeuroPace in a report on Wednesday, July 29th. Finally, Weiss Ratings downgraded shares of NeuroPace from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, October 2nd.

NeuroPace Trading Down 4.2%

Shares of NPCE stock opened at $12.24 on Friday. The company has a market capitalization of $420.08 million, a P/E ratio of -21.47 and a beta of 1.86. The company has a current ratio of 4.94, a quick ratio of 3.91 and a debt-to-equity ratio of 4.97. The business’s 50 day moving average is $14.01 and its two-hundred day moving average is $15.17. NeuroPace has a twelve month low of $9.22 and a twelve month high of $19.60.

NeuroPace (NASDAQ:NPCE) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.04. NeuroPace had a negative return on equity of 105.64% and a negative net margin of 19.34%. The business had revenue of $22.83 million during the quarter, compared to analysts’ expectations of $22.61 million. Equities analysts forecast that NeuroPace will post -0.67 EPS for the current year.

Institutional Investors Weigh In On NeuroPace

A number of institutional investors have recently added to or reduced their stakes in NPCE. BlackRock Inc. purchased a new stake in NeuroPace in the 2nd quarter valued at approximately $39,369,000. First Light Asset Management LLC increased its position in NeuroPace by 82.3% during the 1st quarter. First Light Asset Management LLC now owns 2,459,966 shares of the company’s stock worth $32,349,000 after purchasing an additional 1,110,484 shares during the period. Deutsche Bank AG purchased a new position in shares of NeuroPace during the 2nd quarter worth approximately $14,919,000. GSA Capital Partners LLP purchased a new position in shares of NeuroPace during the 2nd quarter worth approximately $1,836,000. Finally, Man Group plc purchased a new position in shares of NeuroPace during the 2nd quarter worth approximately $1,336,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

NeuroPace Company Profile

NeuroPace, Inc is a medical device company focused on developing and commercializing therapies for people with drug-resistant epilepsy. The company’s principal product is the RNS System, an implantable responsive neurostimulation device designed to monitor brain activity, identify abnormal electrical patterns associated with seizures, and deliver targeted stimulation intended to help prevent or reduce seizures.

The RNS System includes an implanted neurostimulator, leads placed in or on the brain, and external tools that support device programming, patient monitoring, and the collection of seizure-related data.